2024 World Conference on Lung Cancer (WCLC) - Posters-P4.11E.23 Real-World Data (RWD) Of First-Line Cemiplimab Single Agent for Advanced PD-L1 High Expression, Non-Small Cell Lung Cancer (NSCLC)

P4.11E.23 Real-World Data (RWD) Of First-Line Cemiplimab Single Agent for Advanced PD-L1 High Expression, Non-Small Cell Lung Cancer (NSCLC)

Back to course

Pdf Summary

This study examined the real-world effectiveness and safety of cemiplimab as a first-line treatment for advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression (≥50%). Conducted across 16 Spanish institutions, it involved 102 patients treated between May 2022 and July 2023. The results indicated a median progression-free survival (PFS) of 8.1 months, while the median overall survival (OS) was not reached within the median follow-up of 9.8 months.<br /><br />The study found a 53.1% overall radiological response rate, with a complete response in 5.1% of patients. It reported immune-related adverse events (irAEs) in 28.5% of patients, with 15.7% discontinuing treatment due to these side effects. Notably, only one case resulted in death. The analysis identified significant factors affecting clinical outcomes, including extrathoracic disease presence and ECOG performance status, impacting both PFS and OS.<br /><br />The demographics showed a median patient age of 70, with a predominance of males (82%). A large majority had a history of smoking. The study provided robust real-world data supporting cemiplimab's potential as an effective monotherapy, aligning with prior clinical trial findings, and highlighting its safety profile and effectiveness similar to other PD-1/PD-L1 inhibitors. Moreover, it underscored the importance of certain clinical characteristics, like extrathoracic disease, in determining patient outcomes.

Asset Subtitle

Silvia Masini

Meta Tag

Speaker Silvia Masini

Topic Metastatic NSCLC – Immunotherapy

Keywords

cemiplimab

NSCLC

PD-L1 expression

progression-free survival

overall survival

radiological response

immune-related adverse events

extrathoracic disease

ECOG performance status

real-world data